Search

Your search keyword '"Valentina Guadalupi"' showing total 65 results

Search Constraints

Start Over You searched for: Author "Valentina Guadalupi" Remove constraint Author: "Valentina Guadalupi"
65 results on '"Valentina Guadalupi"'

Search Results

1. A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

2. Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational studyResearch in context

3. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio

4. Second-line treatment in renal cell carcinoma: clinical experience and decision making

5. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)

6. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

7. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer

8. Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron

9. From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

11. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

12. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

13. Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects

14. Collecting ducts carcinoma: In depth exploration and biologically driven therapy (CICERONE)

15. The emerging role of PARP inhibitors in prostate cancer

16. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)

17. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)

18. Biomarker-driven immunotherapy for precision medicine in prostate cancer

19. Update on radioligand therapy with

20. Second-line treatment in renal cell carcinoma: clinical experience and decision making

21. Molecular analyses of metastatic collecting ducts renal cell carcinoma from the phase 2 prospective trial of cabozantinib as first-line treatment (BONSAI trial Meeturo 2)

22. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma

23. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

24. Current Understanding of Urachal Adenocarcinoma and Management Strategy

25. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational trial by FICOG

26. 1610P Delivery of ONCOlogic care at HOME: Ready for 'ONCOHOME'

27. 654MO A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)

28. 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic

29. Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma

30. A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information—NCT03354884

31. A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681)

32. A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease

33. Clinical safety and activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy (ARCADIA): Preliminary results from a nonrandomized, open-label, phase 2 trial

34. 736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial

35. Osteonecrosis of the jaw in metastatic renal cell carcinoma (mRCC) patients treated with zolendronic acid and denosumab: An observational retrospective multicenter trial

36. A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36)

37. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes

38. Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?

39. Transcriptomic profiling as proof of concept for investigation of collecting duct carcinoma (CDC)

40. Third-line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: Case report

41. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

42. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration

43. From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

44. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience

45. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

46. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration

47. Neuroendocrine tumors (NETs)

48. Sorafenib in Hepatocellular Carcinoma

49. Activity of sunitinib in patients with advanced neuroendocrine tumors

50. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma

Catalog

Books, media, physical & digital resources